What the clinical data shows at three years

Three years of follow-up data from the prospective post-market clinical follow-up (PMCF) study by Jerosch et al. provide the clearest answer available. Patients treated with ChondroFiller™ showed a mean IKDC score improvement of 32.4 points — nearly double the 16.7-point Minimal Clinically Important Difference (MCID) threshold that defines a change patients actually notice in daily life. At the 36-month mark, mean IKDC scores reached 80, a level that corresponds to near-normal knee function rather than marginal symptom relief.

Structural MRI data corroborates what patients report feeling. European multi-site studies using the MOCART scoring system consistently return values of 81.6–84.3, reflecting greater than 80% volumetric fill of the original defect with repair tissue that integrates well at its borders with the surrounding native cartilage. MOCART scores progressed from a mean of 65.3 at four weeks to 81.6 at one year, confirming that the structural gains are progressive rather than immediate.

The trajectory of these outcomes matters as much as the peak figures. Across the 1–3 year window, gains appear stable rather than declining after an early honeymoon period — the durability signal that most distinguishes ChondroFiller™ from palliative options. Success rates for meaningful pain relief and functional mobility sit at 70–85% in published series, and the reoperation rate of 3–8% compares markedly with microfracture's figure of up to 41%.

The biology behind results that hold over time

Durability of this kind does not arise by chance — it follows from what the treatment is doing inside the joint.

Once placed under ultrasound guidance, the injectable collagen solution gels within 3–5 minutes, forming a dimensionally stable scaffold that anchors to the base and walls of the defect. That rapid in-situ setting is the starting point, not the outcome. What follows is a staged biological sequence: within days to weeks, progenitor cells migrate into the matrix from the surrounding synovium and subchondral bone — a process called acellular matrix-induced chondrogenesis, in which the scaffold itself drives cell recruitment without relying on cells introduced from outside.

A 2025 ex vivo osteochondral study put direct numbers on this process: treated defects showed a 2.4-fold increase in DNA content by day 14 compared with untreated controls, confirming that the scaffold actively draws in host cells rather than merely occupying space. From that point the timeline extends over months: the recruited cells progressively mature and fill the defect with new tissue over approximately 12 months, while the collagen matrix itself is gradually resorbed. By one to two years, the scaffold has gone entirely and is replaced by the patient's own hyaline-like repair tissue.

That tissue quality distinction matters for long-term outcomes. Hyaline-like cartilage is structurally better suited to withstanding joint load than the fibrocartilage produced by marrow-stimulation procedures such as microfracture — and it is the reason that the functional gains seen at three years reflect a biologically rebuilt joint surface, not a temporarily masked one.

Which patients tend to see the best long-term outcomes

The eligibility criteria for ChondroFiller™ are not administrative gatekeeping — they define the structural environment in which the biological sequence described above can actually complete. Four factors are particularly significant as predictors of durable outcomes.

• Focal cartilage loss, Grade III or IV (Outerbridge scale). The scaffold is designed to fill a contained defect, not to address the diffuse joint-surface loss of established osteoarthritis. A defined void with coherent walls gives the matrix somewhere to anchor and cells somewhere to organise.
• Intact surrounding cartilage. The native cartilage at the defect margin forms the structural border into which new repair tissue integrates. Where that margin is itself degraded, integration is less reliable and long-term gains may be diminished.
• Meniscus status. An intact meniscus — or one with no more than one-third resected — preserves the load-sharing mechanics of the compartment. Greater meniscal loss shifts force distribution in ways that may work against the maturing repair zone.
• Physiological leg axis and free joint mobility. Malalignment or restricted movement concentrates mechanical stress on the regenerating surface at precisely the point when the repair tissue is most vulnerable.

Where one or more of these conditions is borderline, providers may consider combination approaches rather than ChondroFiller™ alone. Individual suitability depends on clinical examination and imaging — both assessable at an outpatient appointment.

How rehabilitation consolidates the results

Results at three years are shaped, in large part, by what happens in the first six to twelve weeks after injection.

The collagen scaffold needs an undisturbed environment to allow cell migration and early tissue organisation to proceed. For that reason, the standard post-injection protocol calls for protected weight-bearing during the first four to six weeks — a real commitment that patients are advised to plan around in advance. Partial loading, rather than full immobilisation, is the goal, but impact and unrestricted joint loading are avoided while the scaffold stabilises.

Once that initial phase is complete, a supervised physiotherapy programme introduces progressive loading matched to the tissue maturation timeline. The pace is deliberate: the evidence base treats rehabilitation as an active driver of outcome consolidation, not optional aftercare appended to the injection itself.

Patients who understand this sequence tend to hold more realistic expectations. Meaningful improvement typically begins to emerge at six to twelve weeks, with gains continuing to build across the first twelve months as new tissue matures within the joint.

The 5-year horizon — what the evidence can and cannot yet confirm

Beyond three years, the evidence shifts from controlled follow-up to aggregate clinical observation — a distinction worth stating plainly. The 5-year durability figure that appears in clinical practice reflects that trajectory rather than a replicated, randomised endpoint. Thirty-six months is the current outer boundary of peer-reviewed controlled data; the projection to five years rests on the stability of those 36-month gains and on what the scaffold has, by that point, already produced inside the joint. Once the body's own repair tissue has replaced the resorbed collagen matrix — a process largely complete by 18 to 24 months — the joint is not maintaining an implant; it is maintaining its own tissue. That biological logic supports the durability projection credibly, even where long-term controlled evidence has not yet caught up.

A few additional limitations are worth naming once. Published cohort studies in the literature draw substantially on arthroscopic delivery routes; the ultrasound-guided outpatient pathway that characterises current clinical practice has a shorter published record, though the scaffold biology is the same regardless of how placement is achieved. Success rates across studies — 70 to 85% for meaningful symptom relief — carry wide enough confidence intervals that direct cross-study comparison warrants caution, particularly given differences in outcome measures between trials. No head-to-head randomised trial against hyaluronic acid or ACI at three years has been published.

These are honest gaps in a still-developing evidence base, not reasons to doubt what 36 months of prospective follow-up has already demonstrated.

When combination approaches and monitoring are considered

Not every patient arrives with a textbook-ideal profile. In cases of borderline Kellgren-Lawrence Grade III or IV osteoarthritis alongside a focal cartilage defect, a combination approach may be considered — though each component must be understood on its own terms.

Where ChondroFiller™ is used alongside Arthrosamid, the two products are working through distinct mechanisms. ChondroFiller™ remains the regenerative scaffold component, recruiting the patient's own progenitor cells to restore the focal defect. Arthrosamid is a non-regenerative polyacrylamide hydrogel that addresses the OA joint environment mechanically; it does not repair cartilage and should not be treated as equivalent to, or interchangeable with, the scaffold pathway. Collapsing them into a single category would misrepresent the clinical rationale for using both.

For patients within a longer-term joint preservation programme, some providers use periodic MRI review — typically at around 12 months and at intervals thereafter — to assess repair-tissue quality and defect coverage. Where imaging identifies partial degeneration or incomplete fill, a further ChondroFiller™ injection may be considered at that stage. This monitoring-and-top-up approach is most relevant in more demanding joint environments where the aim is to forestall progression to joint replacement; it is not a standard recommendation for every patient.

Whether a single-course pathway or a combination approach is appropriate requires a thorough specialist assessment — covering OA grade, defect size and location, meniscal and ligamentous status, and limb alignment — supported by imaging review. These are not factors that clinical history alone can establish, and they determine which, if any, of these strategies is likely to produce durable benefit.